GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody ...

The median radiographic progression-free survival was 9.5 months with 177Lu-PNT2002 and 6.0 months with an androgen-receptor pathway inhibitor. 177 Lu-PNT2002 can improve progression-free survival ...

A new type of prostate cancer therapy that is used only in late-stage treatment where conventional therapy has failed has ...

A targeted radioactive infusion that is a game-changer in late-stage prostate cancer can also dramatically improve outcomes ...

ANSTO congratulated the Peter Macallum Cancer Centre led team, who recently reported the remarkable results of late-stage ...

002). The combination of 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto) with docetaxel improved outcomes in patients metastatic hormone-sensitive prostate cancer (mHSPC) without an ...

Not only does lutetium-177-PSMA-617 lower PSA levels in men with metastatic prostate cancer (mCRPC), PSA decline correlates with outcomes, research shows.

A targeted radioactive therapy used to treat late-stage prostate cancer is also effective for patients in the early stages of the disease Australian ...

Cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) in patients with previously treated, ...

Combining radium-223 with enzalutamide offered a survival benefit in metastatic castration-resistant prostate cancer, but experts questioned its relevance in a shifting treatment landscape.